Day One to Participate in the Cowen 43rd Annual Health Care Conference

Rhea-AI Summary

Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company focused on pediatric cancer treatments, announced its participation in the Cowen 43rd Annual Health Care Conference on March 7, 2023, at 9:10 a.m. ET. The company aims to address unmet needs in pediatric cancer therapy with its lead product candidate, tovorafenib (DAY101), a targeted oral treatment. Additionally, an archived webcast will be accessible for 30 days following the event. Day One is dedicated to redefining cancer drug development for all ages from the first day of diagnosis.

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced management will participate in a fireside chat at the Cowen 43^rd Annual Health Care Conference on Tuesday, March 7 at 9:10 a.m. ET.

A live audio webcast of the discussion will be available by visiting the Events & Presentations section of the Company’s website. An archived replay of the webcast will be available for 30 days following the live presentation.

About Day One Biopharmaceuticals
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company that believes when it comes to pediatric cancer, we can do better. We put kids first and are developing targeted therapies that deliver to their needs. Day One was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. The Company’s name was inspired by the “The Day One Talk” that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One.

Day One partners with leading clinical oncologists, families and scientists to identify, acquire and develop important emerging cancer treatments. The Company’s lead product candidate, tovorafenib (DAY101), is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor. The Company’s pipeline also includes pimasertib, an investigational, oral, highly-selective small molecule inhibitor of mitogen‐activated protein kinases 1 and 2 (MEK-1/-2). Day One is based in South San Francisco. For more information, please visit www.dayonebio.com or find the company on LinkedIn or Twitter.

DAY ONE MEDIA
Laura Cooper, Head of Communications
media@DayOneBio.com

DAY ONE INVESTORS
LifeSci Advisors, Hans Vitzthum
hans@lifesciadvisors.com

FAQ

When is Day One Biopharmaceuticals participating in the Cowen Annual Health Care Conference?

Day One Biopharmaceuticals will participate in the Cowen 43rd Annual Health Care Conference on March 7, 2023, at 9:10 a.m. ET.

Where can I watch the Day One Biopharmaceuticals webcast?

The live audio webcast of Day One Biopharmaceuticals' discussion will be available on the company's website in the Events & Presentations section.

What is Day One Biopharmaceuticals' focus?

Day One Biopharmaceuticals is focused on developing targeted therapies for pediatric cancer and addressing the unmet needs in this area.

What is tovorafenib (DAY101)?

Tovorafenib (DAY101) is an investigational, oral, highly-selective type II pan-RAF kinase inhibitor being developed by Day One Biopharmaceuticals.

How long will the Day One Biopharmaceuticals webcast be available for replay?

The archived replay of the Day One Biopharmaceuticals webcast will be available for 30 days following the live presentation.